Skip to main content
SpringerLink
Log in

Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The increasing interest in the subjective wellbeing and quality of life (QoL) of patients with schizophrenia represents a conceptual extension of therapeutic outcome criteria. For a long time, the reduction of positive symptoms alone was the most important outcome parameter, but the development of atypical antipsychotic drugs in the early 1990s resulted in the adoption of more wide-reaching measures of therapeutic outcome. Patient satisfaction appears to be strongly related to their willingness to be or stay engaged in psychosocial and pharmacological treatment, and therefore to the symptomatic and functional outcome. Existing studies that deal with QoL and subjective wellbeing differ in their methodology and are difficult to compare because of varying underlying concepts of QoL or subjective wellbeing, different assessment scales or small sample sizes. Although QoL is a heterogeneous concept, it is clearly correlated with a number of factors, including illness, medication and stress process-related variables. Various protective factors have been identified; among these are personality traits, the degree of social support and treatment interventions. In clinical studies, atypical antipsychotic agents are associated with greater improvements in QoL and subjective wellbeing than are conventional agents. The reason for this is probably the ability of atypical agents to have a positive impact on factors most associated with QoL, such as negative and affective symptoms and drug tolerability. The most appropriate clinical approach to maximize QoL and subjective wellbeing for patients with schizophrenia is to use atypical antipsychotic drugs as a first-line treatment approach. Ideally, an atypical drug which is known not to have a negative effect on attention, affect or motivation should be chosen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Albrecht GL, Fitzpatrick R, editors. A sociological perspective on health-related quality of life research. In: Advances in medical sociology — quality of life in health care. London: Jai Press; 1994

  2. Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Prog Plann 1983; 6: 143–51

    Article  CAS  Google Scholar 

  3. Malm U, May PR, Dencker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7: 477–87

    Article  PubMed  CAS  Google Scholar 

  4. Bullinger M, Hasford J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 1991; 12(4 Suppl.): 91S–105S

    Article  PubMed  CAS  Google Scholar 

  5. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Commun Psychiatry 1992; 43: 262–5

    CAS  Google Scholar 

  6. Zissi A, Barry MM, Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychol Med 1998; 28: 1221–30

    Article  PubMed  CAS  Google Scholar 

  7. Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenia symptoms. Qual Life Res 2003; 12: 1–9

    Article  PubMed  CAS  Google Scholar 

  8. Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31–8

    Article  PubMed  CAS  Google Scholar 

  9. Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res 2003; 3: 89–99

    Article  Google Scholar 

  10. Angermeyer MC, Holzinger A, Kilian R, et al. Quality of life — as defined by schizophrenic patients and psychiatrists. Int J Soc Psychiatry 2001; 47: 34–42

    Article  PubMed  CAS  Google Scholar 

  11. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609–18

    Article  PubMed  CAS  Google Scholar 

  12. Noll RL, Hoenkamp E, Nolen WA. Subjectieve bijwerkingen van neuroleptics. Nederlands Tijdschrift voor Geneeskunde 1991; 135: 2113–6

    PubMed  CAS  Google Scholar 

  13. de Haan L. Patients perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia. Amsterdam: University of Amsterdam; 2001.

    Google Scholar 

  14. Van Putten T, May RP. ‘Akinetic depression’ in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101–7

    Article  PubMed  Google Scholar 

  15. Wise RA. Neuroleptic-induced anhedonia. Recent studies. In: Tamminga CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology. New York: Raven Press; 1991. pp. 323–31

    Google Scholar 

  16. Emerich DF, Sanberg PR. Neuroleptic dysphoria. Biol Psychiatry 1991; 29: 201–3

    Article  PubMed  CAS  Google Scholar 

  17. Lewander T. Neuroleptics an the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scand 1994; 380 (Suppl.): 8–13

    Article  CAS  Google Scholar 

  18. Lambert M, Schimmelman B, Karow A, et al. Subjective well-being under neuroleptic treatment — concepts measurement, clinical relevance and implications for anti-psychotic treatment. Pharmacopsychiatry 2003; 36(Suppl. 3): 181–90

    Google Scholar 

  19. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10(Suppl. 3): 133–8

    PubMed  Google Scholar 

  20. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? Management issues in schizophrenia: patient satisfaction, compliance and outcomes in schizophrenia. Clear Perspect 1999; 2: 1–6

    Google Scholar 

  21. Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41: 349–55

    Article  PubMed  CAS  Google Scholar 

  22. Browne S, Garavan J, Gervin M, et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186: 74–8

    Article  PubMed  CAS  Google Scholar 

  23. Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28: 165–72

    Article  PubMed  CAS  Google Scholar 

  24. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  25. Diamond R, Becker M. The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. J Clin Psychiatry 1999; 60(Suppl. 3): 29–31

    PubMed  Google Scholar 

  26. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  27. Oliver JP, Huxley PJ, Priebe S, et al. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 76–83

    Article  PubMed  CAS  Google Scholar 

  28. Pukrop R, Moller HJ, Sass H, et al. Quality of life. Construct validation and the development of a modular system. Nervenartz 1999; 70: 41–53

    Article  CAS  Google Scholar 

  29. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988; 11: 51–62

    Article  Google Scholar 

  30. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98

    Article  PubMed  CAS  Google Scholar 

  31. Jaeger J, Bitter I, Czobor P, et al. The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Comprehen Psychiatry 1990; 31: 216–26

    Article  CAS  Google Scholar 

  32. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976; 37: 191–6

    PubMed  CAS  Google Scholar 

  33. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177–83

    Article  PubMed  CAS  Google Scholar 

  34. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79–88

    Article  PubMed  CAS  Google Scholar 

  35. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56: 37–46

    Article  PubMed  Google Scholar 

  36. Carpiniello B, Lai GL, Pariante CM, et al. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed outpatients. Acta Psychiatrica Scand 1997; 96: 235–41

    Article  CAS  Google Scholar 

  37. Skantze K, Malm U, Dencker SJ, et al. Comparison of quality of life with standard of living in schizophrenic out-patients. Br J Psychiatry 1992; 161: 797–801

    Article  PubMed  CAS  Google Scholar 

  38. Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res 1993; 2: 327–33

    Article  PubMed  CAS  Google Scholar 

  39. Hansson L, Middelboe T, Merinder L, et al. Predictors of subjective quality of life in schizophrenic patients living in the community. A Nordic multicentre study. Int J Soc Psychiatry 1999; 45: 247–58

    Article  PubMed  CAS  Google Scholar 

  40. Browne S, Clarke M, Gervin M, et al. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000; 176: 173–6

    Article  PubMed  CAS  Google Scholar 

  41. Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64: 308–15

    Article  PubMed  Google Scholar 

  42. Awad AG, Hogan TP, Voruganti LN, et al. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10(Suppl. 3): 123–32

    PubMed  Google Scholar 

  43. de Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002; 162: 24–8

    Article  Google Scholar 

  44. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003; 191: 287–94

    PubMed  Google Scholar 

  45. Tollefson GD, Andersen SW, Tran PV The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46: 365–73

    Article  PubMed  CAS  Google Scholar 

  46. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 2001; 189: 669–75

    Article  PubMed  CAS  Google Scholar 

  47. Bow-Thomas CC, Velligan DI, Miller AL, et al. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999; 86: 131–42

    Article  PubMed  CAS  Google Scholar 

  48. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94: 118–24

    Article  PubMed  CAS  Google Scholar 

  49. Giner J, Ibanez E, Cervera S, et al. Subjective experience and quality of life in schizophrenia [in Spanish]. Actas Esp Psiquiatr 2001; 29: 233–42

    PubMed  CAS  Google Scholar 

  50. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155: 1196–201

    PubMed  CAS  Google Scholar 

  51. Moritz S, Krausz M, Gottwalz E, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000; 33: 48–51

    Article  PubMed  CAS  Google Scholar 

  52. Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997; 22: 235–43

    PubMed  CAS  Google Scholar 

  53. Kaiser W. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. Br J Psychiatry 2000; 176: 92–3

    Article  PubMed  CAS  Google Scholar 

  54. Aksaray G, Oflu S, Kaptanoglu C, et al. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1217–9

    Article  PubMed  Google Scholar 

  55. Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 2001; 27: 697–708

    Article  PubMed  CAS  Google Scholar 

  56. Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102: 303–9

    Article  PubMed  CAS  Google Scholar 

  57. Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61:880–9; quiz 90

    Article  PubMed  CAS  Google Scholar 

  58. Doyle M, Flanagan S, Browne S, et al. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999; 99: 466–72

    Article  PubMed  CAS  Google Scholar 

  59. Lysaker PH, Bell MD, Bryson GJ, et al. Insight and interpersonal function in schizophrenia. J Nerv Ment Dis 1998; 186: 432–6

    Article  PubMed  CAS  Google Scholar 

  60. Day JC, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 1998; 97: 93–7

    Article  PubMed  CAS  Google Scholar 

  61. Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405–9

    Article  PubMed  CAS  Google Scholar 

  62. Lambert M, Conus P, Eide P, et al. Impact of present and past side effects on the attitude towards typical anti-psychotic treatment. European Psychiatry submitted.

  63. Van Putten T, Marder SR. Behavioral toxicity of anti-psychotic drugs. J Clin Psychiatry 1987; 48 (Suppl.): 13–9

    Google Scholar 

  64. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–7

    Article  PubMed  Google Scholar 

  65. Hofer A, Kemmler G, Eder U, et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63: 49–53

    Article  PubMed  Google Scholar 

  66. Knudstorp TB, Gerlach J. Quality of life (QoL) in chronic schizophrenic patients related to symptoms, side-effects and subjective distress. In: Proceedings of the XIth World Congress on Psychiatry. Hamburg, Germany, 1999

  67. Jarema M, Murawiec S, Szafranski T, et al. Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs [in Polish]. Psychiatr Pol 2001; 35: 5–19

    PubMed  CAS  Google Scholar 

  68. Van Putten T, May PR, Marder SR. Response to anti-psychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 1984; 141: 16–9

    PubMed  Google Scholar 

  69. Ritsner M, Modai I, Ponizovsky A. Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. Compr Psychiatry 2002; 43: 229–34

    Article  PubMed  Google Scholar 

  70. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001; 16: 153–62

    Article  PubMed  CAS  Google Scholar 

  71. Lasalvia A, Ruggeri M, Santolini N. Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychosom 2002; 71: 275–84

    Article  PubMed  Google Scholar 

  72. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993; 22: 39–44

    Google Scholar 

  73. Eklund M, Backstrom M, Hansson L. Personality and self-variables: important determinants of subjective quality of life in schizophrenia out-patients. Acta Psychiatr Scand 2003; 108: 134–43

    Article  PubMed  CAS  Google Scholar 

  74. Bechdolf A, Klosterkotter J, Hambrecht M, et al. Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003; 253: 228–35

    Article  PubMed  Google Scholar 

  75. Bengtsson-Tops A, Hansson L. Quantitative and qualitative aspects of the social network in schizophrenic patients living in the community. Relationship to sociodemographic characteristics and clinical factors and subjective quality of life. Int J Soc Psychiatry 2001; 47: 67–77

    Article  PubMed  CAS  Google Scholar 

  76. Borge L, Martinsen EW, Ruud T, et al. Quality of life, loneliness, and social contact among long-term psychiatric patients. Psychiatr Serv 1999; 50: 81–4

    PubMed  CAS  Google Scholar 

  77. Hansson L, Eklund M, Bengtsson-Tops A. The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community. Qual Life Res 2001; 10: 133–9

    Article  PubMed  CAS  Google Scholar 

  78. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162: 3–10

    Article  CAS  Google Scholar 

  79. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–45

    Article  PubMed  CAS  Google Scholar 

  80. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201–8

    Article  PubMed  CAS  Google Scholar 

  81. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693–702

    Article  PubMed  CAS  Google Scholar 

  82. de Haan L, Peters B, Dingemans P, et al. Attitudes of patients toward the first psychotic episode and the start of treatment. Schizophr Bull 2002; 28: 431–42

    Article  PubMed  Google Scholar 

  83. Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 463–5

    Article  PubMed  CAS  Google Scholar 

  84. Dollfus S, Ribeyre JM, Petit M. Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. Psychopathology 2000; 33: 125–30

    Article  PubMed  CAS  Google Scholar 

  85. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10(Suppl. 3):105–14

    PubMed  Google Scholar 

Download references

Acknowledgements

Professor Naber was co-chair of the Sertindole Roundtable Meeting, Copenhagen, Denmark, held on 3 October 2003. Dr Lambert has been the recipient of lecture and research honoraria from H. Lundbeck A/S.

Author information

Authors and Affiliations

  1. Department for Psychiatry and Psychotherapy, University of Hamburg, Centre for Psychosocial Medicine, Martinistreet 52, 20246, Hamburg, Germany

    Martin Lambert & Dieter Naber

Authors
  1. Martin Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Lambert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lambert, M., Naber, D. Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life. CNS Drugs 18 (Suppl 2), 5–17 (2004). https://doi.org/10.2165/00023210-200418002-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418002-00002

Keywords

Search

Navigation